LLY

818.19

-0.05%↓

JNJ

155.09

-1.15%↓

ABBV

190.37

-0.11%↓

NVO

77.18

-3.21%↓

UNH

306.5

-2.15%↓

LLY

818.19

-0.05%↓

JNJ

155.09

-1.15%↓

ABBV

190.37

-0.11%↓

NVO

77.18

-3.21%↓

UNH

306.5

-2.15%↓

LLY

818.19

-0.05%↓

JNJ

155.09

-1.15%↓

ABBV

190.37

-0.11%↓

NVO

77.18

-3.21%↓

UNH

306.5

-2.15%↓

LLY

818.19

-0.05%↓

JNJ

155.09

-1.15%↓

ABBV

190.37

-0.11%↓

NVO

77.18

-3.21%↓

UNH

306.5

-2.15%↓

LLY

818.19

-0.05%↓

JNJ

155.09

-1.15%↓

ABBV

190.37

-0.11%↓

NVO

77.18

-3.21%↓

UNH

306.5

-2.15%↓

Search

Arcus Biosciences Inc

Open

SectorHealthcare

9.11 -1.41

Overview

Share price change

24h

Current

Min

8.96

Max

9.25

Key metrics

By Trading Economics

Income

-18M

-112M

Sales

2M

28M

EPS

-1.14

Profit margin

-400

Employees

627

EBITDA

-34M

-122M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+173.7% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

90M

1.1B

Previous open

10.52

Previous close

9.11

News Sentiment

By Acuity

50%

50%

142 / 381 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Neutral Evidence

Arcus Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 cze 2025, 23:40 UTC

Acquisitions, Mergers, Takeovers

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- 2nd Update

15 cze 2025, 23:27 UTC

Acquisitions, Mergers, Takeovers

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- Update

15 cze 2025, 23:10 UTC

Acquisitions, Mergers, Takeovers

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium

13 cze 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380 Million

15 cze 2025, 23:50 UTC

Market Talk

Gold Edges Higher Amid Likely Safe-Haven Demand -- Market Talk

15 cze 2025, 23:47 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over Middle East -- Market Talk

15 cze 2025, 23:41 UTC

Market Talk

Oil Rises Amid Middle East Tensions -- Market Talk

15 cze 2025, 23:33 UTC

Market Talk

China Most Affected by Any Disruption to Iran Crude Oil Exports -- Market Talk

15 cze 2025, 23:29 UTC

Market Talk

Oil Price Could Rise More This Week -- Market Talk

15 cze 2025, 23:27 UTC

Market Talk

Fed's Powell Likely to Emphasize Ongoing Policy Patience -- Market Talk

15 cze 2025, 23:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 cze 2025, 23:02 UTC

Market Talk

Global Energy Roundup: Market Talk

15 cze 2025, 23:02 UTC

Market Talk

Rising Middle East Tensions Could Be Passing Storm for World Economy -- Market Talk

15 cze 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

Santos Says Recommendation Requires Independent Expert Concluding Offer Is Fair, Reasonable

15 cze 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

Santos Intends to Recommend Shareholders Vote In Favor of Transaction If Binding Offer Made

15 cze 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Santos Intends to Negotiate Terms of Process, Exclusivity Deed With XRG Consortium

15 cze 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Santos to Give XRG Consortium Due Diligence Access

15 cze 2025, 22:45 UTC

Acquisitions, Mergers, Takeovers

Santos Says XRG Consortium Offer Is Final, Had Made Two Earlier Proposals

15 cze 2025, 22:45 UTC

Acquisitions, Mergers, Takeovers

Santos Says XRG Consortium Offering A$8.89/Share in Cash

15 cze 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

Santos Says XRG Consortium Includes Abu Dhabi Development Holding Co and Carlyle

15 cze 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

Santos Gets Takeover Offer From Consortium Led by Abu Dhabi's Adnoc

15 cze 2025, 22:31 UTC

Market Talk

Gold Price Can Push Toward New All-Time High -- Market Talk

14 cze 2025, 01:24 UTC

Acquisitions, Mergers, Takeovers

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13 cze 2025, 23:50 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 cze 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 cze 2025, 23:09 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 cze 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 cze 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380M

13 cze 2025, 22:04 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 cze 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

Peer Comparison

Price change

Arcus Biosciences Inc Forecast

Price Target

By TipRanks

173.7% upside

12 Months Forecast

Average 25.29 USD  173.7%

High 46 USD

Low 12 USD

Based on 9 Wall Street analysts offering 12 month price targets forArcus Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

8.01 / 8.75Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Neutral Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

142 / 381 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.